

## **INSIDER INFORMATION LABIANA HEALTH, S.A.**

Madrid, October 23, 2023

Pursuant to the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse and Article 228 of Law 6/2023 of 17 March on Securities Markets and Investment Services, and concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity (hereinafter "BME Growth"), LABIANA HEALTH, S.A. (hereinafter "LABIANA" or "the Company") communicates the following information:

### **TREASURY STOCK PURCHASE PROGRAM**

The Company publishes a free translation of the publication issued to the Market on October 17 regarding the Board of Directors of the Company held on September 25, 2023 resolved to approve a treasury stock repurchase program (the "Repurchase Program"), pursuant to the authorization granted by the sixth resolution of the General Shareholders' Meeting held on March 4, 2022, for the derivative acquisition of the Company's own shares.

The Buyback Program, which is established in accordance with the provisions of Section 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, will be carried out on the terms set out below:

#### **1. Objective**

The Company is in the process of evaluating and designing a stock option program as an incentive for managers. The objective of the Repurchase Program will be to comply with the obligations arising from the stock option program.

#### **2. Maximum number of shares and maximum investment**

The maximum number of shares to be acquired under the Repurchase Program will be a maximum of 100,000 treasury shares representing approximately 1.38% of the Company's share capital as of the date of this communication. Alternatively, the maximum investment that LABIANA will allocate to the Repurchase Program amounts to a maximum of 300,000 euros.

#### **3. Price and volume conditions**

The shares will be purchased by the Company at market price, in accordance with the price and volume conditions set out in Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 and subject to the terms authorized by the aforementioned General Shareholders' Meeting. In particular, as regards price, the Company shall not purchase shares at a price higher than the higher of (i) the price of the last independent transaction; or (ii) the highest independent bid at that time on the trading venues where the purchase is made.

With regard to trading volume, LABIANA will not purchase more than 25% of the average daily volume of LABIANA shares in the trading center where the purchase is made. The average daily volume of the Company's shares for the purposes of the above computation shall be based on the average daily volume traded in the twenty (20) business days prior to the date of each purchase.

#### **4. Term of duration**

The Repurchase Program will commence on November 1, 2023 and will remain in force until March 31, 2024. However, LABIANA reserves the right to terminate the Repurchase Program if, prior to its expiration date, its purpose has been fulfilled and, in particular, if LABIANA has acquired under the Program the number of shares, or shares for an acquisition price that reaches the amount of the maximum investment, or if any other circumstance requires so.

The interruption, termination or modification of the Repurchase Program, as well as the share purchase transactions carried out by virtue thereof, shall be duly notified to BME Growth by means of the corresponding communication, with the frequency provided for in the Delegated Regulations and shall be published on the Company's website.

#### **5. Execution (representative manager)**

The Repurchase Program will count with GVC Gaesco Valores, S.V., S.A. as the Company's representative agent, who will carry out the purchase of its own shares on behalf of LABIANA and will make the purchase decisions independently.

The Company will communicate the purchase transactions carried out in execution of the Repurchase Program in accordance with the terms set forth in the regulations in force.

In accordance with the provisions of the aforementioned Circular 3/2020, it is hereby stated that the information provided herein has been prepared under the sole responsibility of the Company and its directors.

Sincerely yours,

D. Manuel Ramos Ortega  
Chief Executive Officer  
LABIANA HEALTH, S.A.